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CHA2DS2-VASc and HAS-BLED clinical risk score. Results: Totally, 10,099 patients 
fulfilled our study criterions. The total annualized direct cost of NVAF patient was 
1,627.9 euro ±1,076.6. The main cost component was the hospitalization (68.0%), 
followed by drug use (24.6%) and outpatient services (7.4%). The predictors of the 
total cost were male (RR: 1.37, CI: 1.29-1.45 versus female), incident (RR: 4.60, CI: 4.30-
4.92 versus prevalent patient), switcher (RR: 1.88, CI: 1.72-2.06 versus no switcher), 
CHA2DS2-VASc score (RR: 6.34, CI:5.08-7.92 for score 7 versus score 0) and HAS-BLED 
(RR: 1.36, CI:1.25-1.48 for score > 3 versus score ≤ 3). ConClusions: NVAF places an 
enormous burden on health care system. Hospitalization as major cost driver high-
lights the potential cost-effectiveness of disease management targeted at reducing 
risks of serious cerebrovascular events among NVAF patients.
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objeCtives: The innovative technologies for aortic stenosis (AS) treatment 
require in-depth analysis of the costs associated with disease and comorbidi-
ties. To quantify health care resources consumed by AS patients’ treatment 
(drugs, diagnostic tests, hospital outpatient and inpatient) and estimate the 
total direct costs. Methods: We conducted a retrospective observational 
cohort analysis using data from administrative databases of Local Health 
Authority of Milan in Italy. The study population included all subjects hospi-
talized with principal or secondary AS diagnosis between January 1, 2007 and 
December 31, 2011 (enrollment period). All subjects were observed for two 
years after the first hospitalization (index hospitalization). Patient characteri-
zation was related to the two years before index hospitalization (characteri-
zation period). Data related to hospitalizations, drugs and hospital outpatient 
during both periods were collected for each patient to quantify the resources 
consumption. The hospitalization costs were estimated using DRG tariffs and 
hospital outpatient costs with regional tariffs. The drugs consumption was evalu-
ated through the tear-off tab prices. Results: 919 patients were included (mean 
age 71.3 ± 11.6; 51% males). The mean cost of illness per patient is € 16,271 and € 
13,916, in the characterization and observation period respectively. Of all treated 
patients, 323 (35 %) underwent surgical procedure. The mean cost of illness for 
these patients is € 28,365 and € 8,002, in the characterization and observation 
period respectively. Considering only costs related to cardiovascular disease, the 
mean cost per patient is € 3,470 and € 2,272 in the characterization and obser-
vation period respectively. ConClusions: The cost of illness in AS patients is 
lower in the period after admission, especially when patients underwent cardiac 
valve treatment.
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objeCtives: Hyperkalemia is a metabolic abnormality seen frequently in the 
Emergency Department. The most common condition leading to hyperkalemia is 
missed dialysis in a patient with end stage renal disease (ESRD), but many other 
conditions can predispose an individual to hyperkalemia, such as acute renal fail-
ure, extensive burns, trauma, or severe rhabdomyolysis or severe acidosis. The 
objective of this study was to assess the resource burden on United States emer-
gency room departments due to hyperkalemia. Methods: The number of emer-
gency room (ED/ ER) visits due to hyperkalemia, with International Classification 
of Diseases (ICD-9) code 276.7, were estimated using the Centers for Medicare & 
Medicaid Services (CMS) Agency for Healthcare Research and Quality (AHRQ) 2011 
data for ED visits. A review of recent publications on hyperkalemia management 
was also conducted using the databases Pubmed, Embase, Biosis, Google Scholar 
and Cochrane. Results: The annual number of ED visits with Hyperkalemia as 
one of the diagnoses is estimated to be 814,181 (SE 23,526). The annual number of 
ED visits with Hyperkalemia as the first listed diagnosis is estimated to be 66,989 
(SE 2284. Among the age groups 18-44, 45-64, 65-84, 85+ the majority of ED visits 
were in the 45-64 (36.04%) and 65-84 (39.44%) groups (hyperkalemia as the first 
listed diagnosis). Among the five payer types, Medicare, Medicaid, Private insurance, 
Uninsured and Other, the majority of patients belonged to Medicare (68.41%). The 
trend was similar for patients with Hyperkalemia as one of the diagnosis or first 
diagnosis. ConClusions: This analysis confirms previous findings that hyper-
kalemia is common in the emergency department. There is a need for quick, safe 
and effective treatments for hyperkalemia, which can be easily administered in 
emergency department setting.
PCV76
eConomIC Burden In dIreCt Costs of oBesIty And oVerweIgHt In 
russIA
Krysanova V, Zhuravleva M
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: The high prevalence of obesity and overweight leads to frequent use 
of health care resources. Studies aimed at assessment of damages caused by this 
medico-social problem are seen as very important at last years. The main aim of this 
study was to assess burden of obesity and overweight in Russia taking as an example 
three main social diseases: stroke, heart attack, and diabetes mellitus. Methods: 
Available evidence on assessment of costs of management and treatment of obese 
and overweight patients and its relation to the disorders selected were analyzed. 
To measure costs of obesity and overweight for the state budget were used “cost 
of illness” analysis with consideration of risks of stroke, heart attack, and diabetes 
mellitus in the population (G. Oster et al, 2000). Taking into account specific fea-
tures of cost assessment and based on publically available data were developed 
costs were € 56,77 and € 39,18 correspondingly. “The cost-efficiency” analysis 
demonstrated that CER in main group was € 67,58 and CER in control group was € 
72,56. ConClusions: The “cost-efficiency” analysis demonstrated that adminis-
tration of tiazotic acid morpholinium salt in combination with standard therapy 
is more effective and less expensive in ACS patients. The obtained results allow to 
optimize treatment expenditures for a state, insurance companies and patients.
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objeCtives: About two-thirds of stroke survivors develop post-stroke sequelae, 
including spasticity. The burden of post-stroke spasticity (PSS) is high in terms of 
treatment costs and the effects of comorbidities. Our objective was to describe the 
burden of PSS in terms of healthcare resource utilization and costs, and quantify 
the difference between patients who develop PSS and those who do not. Methods: 
This retrospective study used the THIN database. Adult patients with a stroke 
between 1Jan2007 and 31Dec2012 were included. PSS diagnoses were found to be 
under-represented; machine learning methodology was applied to identify poten-
tially undiagnosed PSS. Cases were defined as patients with diagnosed or predicted 
PSS in the 12 months after stroke; for patients without PSS, each stroke acted as 
a control event. PSS cases were matched to controls on age, gender, prior strokes, 
socioeconomic status, and comorbidities, using the nearest neighbour algorithm. 
Direct healthcare resources, including primary care visits, all-cause hospitalisations, 
and specialist referrals during the year post-stroke, were costed out at 2014 GBP 
rates, using public sources. Results: Of the 3,082 PSS cases and 28,753 controls, 
56% were female and 49% were 75 years or older. During the first year, 33% of the 
PSS cases were hospitalised, compared to 9% of the controls. Specialist referrals 
were recorded for 76% of PSS patients and 64% of controls. Primary care utilisation 
was similar for both groups. Total average costs per patient were £1,270 (SD: 772) 
for cases and £631 (SD: 496) for controls. After adjusting for other covariates, a sig-
nificant increase in cost for the PSS patients was found; on average £635 in the 12 
months post-stroke. ConClusions: The costs for patients who develop PSS after 
stroke are twice as high as those for patients who do not develop spasticity, with 
the major driver being the number of hospitalisations.
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objeCtives: Estimate the incremental annual cost after a myocardial infarction 
(MI) Methods: A French representative cohort of patients who had a MI in France 
between 2007 and 2011 was extracted from a claim database of 600,000 patients. 
Costs were calculated from a community perspective, restricted to direct costs and 
from a health insurance scheme perspective. This analysis was performed on sub-
jects still alive one year after MI Results: A total of 1,920 subjects were identified 
with an index MI: 2/3 were males, mean age= 67.2 y, 20.6% had diabetes, 37.6% 
hypercholesterolemia and 82.4% hypertension. Among the 1,920 subjects, 346 died in 
the first year and 3 were lost to follow-up: the cost was performed on 1,571 patients. 
The annual cost from a health insurance scheme perspective approximately tripled 
as it increased from € 3,940 to € 11,914 after a MI: Hospital cost increased from € 1,616 
before the index MI to € 6,470 after hospitalization (the cost of the index hospitaliza-
tion is excluded from the cost); Average community-based care costs increased from 
€ 2,323 before the index MI to € 5,443 after: Travel costs increased from 127€ to 573€ ; 
Fees related to physician consultations increased from 589€ to 1,676€ (annual mean 
number consultations with a general practitioner and a specialist increased from 
7.6 to 10.9 and from 5.4 to 10 respectively); Fees related to laboratory tests increased 
from 139€ to 408€ ; Cost of medicinal products increased from 1,105€ to 2,283€ ; Cost 
of medical non physician health professionals increased from 380€ to 534€ . It should 
be noted that the mean cost related to the index MI hospitalization was € 5,876 . The 
evolution of the costs from a community perspective was similar. ConClusions: 
The economic impact of recurrent cardiovascular events is substantial since health-
care consumption costs almost tripled after the index MI event
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objeCtives: To determine the direct healthcare costs associated with non-valvular 
atrial fibrillation (NVAF). Methods: A population-based cohort study was con-
ducted using administrative data from a local health authority in the Campania 
Region (~1,000,000 inhabitants). NVAF was defined as one or more claims for atrial 
fibrillation (ICD-9-CM code 427.31) between January 1, 2005 and June 30, 2014, where 
none of the claims was associated with cardioversion or cardiac ablation and there 
was no evidence of valve-related diagnoses or procedures. All patients were fol-
lowed from June 30, 2014 until death or end of study follow-up (December 31, 2014). 
The direct costs were reported as average annualized cost (per patient per month 
multiplied by 12). Costs were divided into hospitalizations, outpatient services and 
pharmacy claims. Generalised linear mixed models under gamma distribution were 
used to identify predictors of cumulative healthcare costs. Rate Ratios (RRs) and 95% 
confidence intervals (CIs) were adjusted for age, gender, incident patients, switcher, 
